The earnings call highlighted significant progress in clinical trials, regulatory approvals, and collaboration efforts, particularly in oncology and long COVID research. However, financial challenges persist, with reliance on external funding and the impact of noncash charges and nonrecurring costs. While the achievements indicate a strong strategic direction, financial sustainability remains a concern.

Company Guidance -

Q1 2026

During the Aethlon Medical Fourth Quarter Fiscal 2025 Earnings and Corporate Update Conference Call, CEO and CFO Jim Frakes provided guidance on the company's recent progress and financial performance. Notably, Aethlon treated the first three patients in its oncology trial in Australia using the Hemopurifier, with regulatory approval received to initiate a similar study in India. The company also expanded its trial protocol and reported a significant 98.5% removal of platelet-derived extracellular vesicles in preclinical studies. Collaborations with UCSF on long COVID research and streamlined operations led to reduced operating expenses of $9.3 million, a 26% decrease from the previous year. Financially, the company ended the fiscal year with a cash balance of $5.5 million, but recorded a $4.6 million noncash charge from a warrant inducement offer, which raised $2.3 million in cash. Aethlon emphasized its primary focus on oncology, while also exploring opportunities in long COVID research through potential nondilutive grants.

Oncology Trial Progress in Australia

Aethlon Medical treated the first 3 patients in its oncology trial using the Hemopurifier at clinical sites in Australia. The trial completed Hemopurifier treatments without device deficiencies or immediate complications, and the prespecified 7-day safety follow-up was completed.

Regulatory Approval in India

The company received regulatory approval in India to initiate a similar oncology study at Medanta Medicity Hospital, marking a significant step in expanding their clinical trials globally.

Collaboration with UCSF on Long COVID

Aethlon Medical is collaborating with University of California, San Francisco on long COVID research, with findings to be presented at the Keystone Symposium, potentially opening avenues for addressing long COVID.

Significant Reduction in Operating Expenses

Operating expenses were significantly reduced by 26% year-over-year, from $12.6 million to $9.3 million, highlighting effective cost management strategies.

Preclinical Data on Hemopurifier

Preclinical data demonstrated a 98.5% removal of platelet-derived extracellular vesicles in simulated Hemopurifier treatments, reinforcing the potential therapeutic applications of the product.

Aethlon Medical (AEMD) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

AEMD Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 06, 2025	2026 (Q1)	- / -	-0.34	―	―	―
Jun 26, 2025	2025 (Q4)	-1.07 / -3.22	-6.96	53.74% (+3.74)	―
Feb 12, 2025	2025 (Q3)	-1.63 / -1.04	-10.96	90.51% (+9.92)	―
Nov 13, 2024	2025 (Q2)	-1.56 / -1.60	-9.76	83.61% (+8.16)	―
Aug 14, 2024	2025 (Q1)	-2.52 / -2.72	-11.2	75.71% (+8.48)	―
Jun 27, 2024	2024 (Q4)	-9.84 / -6.96	-8	13.00% (+1.04)	―
Feb 14, 2024	2024 (Q3)	-10.80 / -10.96	-9.6	-14.17% (-1.36)	―
Nov 14, 2023	2024 (Q2)	-11.20 / -9.76	-14.4	32.22% (+4.64)	―
Aug 10, 2023	2024 (Q1)	-10.40 / -11.20	-15.2	26.32% (+4.00)	―
Jun 28, 2023	2023 (Q4)	-11.60 / -8.00	-20.8	61.54% (+12.80)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

AEMD Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jun 26, 2025	$1.94	$1.25	-35.57%
Feb 12, 2025	$5.34	$5.05	-5.43%
Nov 13, 2024	$3.25	$3.19	-1.85%
Aug 14, 2024	$3.08	$2.56	-16.88%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Aethlon (AEMD) report earnings?

Aethlon (AEMD) is schdueled to report earning on Aug 06, 2025, After Close (Confirmed).

What is Aethlon (AEMD) earnings time?

Aethlon (AEMD) earnings time is at Aug 06, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is AEMD EPS forecast?

Currently, no data Available

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing